Food, Drugs, Healthcare, Life Sciences

The New Jersey Department of Health (DOH) recently published Responses to Frequently Asked Questions (FAQs) regarding registered surgical practices...

On August 20, 2025, the Ninth Circuit affirmed the dismissal of a securities fraud class action alleging that a pharmaceutical company and certain of its executives...

In the final hours of 2024, Congress passed a six-month extension of the Medicare telehealth flexibilities through its 2025 funding bill, pushing the expiration date to September 30, 2025.

In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit upheld the district court’s determination that the claims at issue were neither obvious nor invalid under the doctrine of obviousness-type double patenting based on a "lead compound" approach to the obviousness determinations.

After the Supreme Court decided that the personalized medicine method claims at issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc. did not satisfy the patent eligibility requirements of 35 USC § 101.

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.

For founders in life sciences and other technology companies, the cap table is fragile by design. Stock is more than a piece of paper, it carries ownership and control over the company.

On September 10, the US Department of Justice (DOJ), working in coordination with the Food and Drug Administration (FDA), the Bureau of Alcohol...

The White House released the long-awaited Make America Healthy Again (MAHA) Strategy Report (the Strategy) on September 9, 2025 to much fanfare, though the report itself was rather lackluster

On August 20, 2025, the Ninth Circuit affirmed the dismissal of a securities fraud class action alleging that a pharmaceutical company and certain of its executives...

On August 27, the Food and Drug Administration (FDA) licensed 2025–2026 versions of the COVID-19 vaccines for individuals age 65 and older and those aged 5 to 64 with at least one underlying condition that puts them at risk for severe COVID-19 outcomes

Earlier this week, the U.S. Food & Drug Administration announced that it is stepping up its enforcement related to misleading prescription drug advertising and is beginning a new rulemaking...